Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lièvre A[au]:

Search results

Items: 1 to 50 of 87

1.

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0328. doi: 10.1634/theoncologist.2019-0328. [Epub ahead of print]

PMID:
31578276
2.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30037-4. doi: 10.1016/j.clcc.2019.08.004. [Epub ahead of print]

PMID:
31564556
3.

Chemotherapy in resected neuroendocrine carcinomas of the digestive tract: a national study from the French Group of Endocrine Tumours (GTE).

Pellat A, Walter T, Augustin J, Hautefeuille V, Hentic O, Do Cao C, Lièvre A, Coriat R, Hammel P, Dubreuil O, Cohen R, Couvelard A, André T, Svrcek M, Baudin E, Afchain P.

Neuroendocrinology. 2019 Aug 21. doi: 10.1159/000502825. [Epub ahead of print]

PMID:
31430756
4.

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.

Gallois C, Artru P, Lièvre A, Auclin E, Lecomte T, Locher C, Marthey L, Zaimi Y, Faroux R, Pernot S, Barret M, Taieb J.

Eur J Cancer. 2019 Sep;119:35-43. doi: 10.1016/j.ejca.2019.07.011. Epub 2019 Aug 12.

PMID:
31415985
5.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J; for PRODIGE 22 investigators/Collaborators.

Ann Surg. 2019 Jul 6. doi: 10.1097/SLA.0000000000003454. [Epub ahead of print]

PMID:
31356278
6.

Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey.

Canouï-Poitrine F, Lièvre A, Dayde F, Lopez-Trabada-Ataz D, Baumgaertner I, Dubreuil O, Brunetti F, Coriat R, Maley K, Pernot S, Tournigand C, Hagege M, Aparicio T, Paillaud E, Bastuji-Garin S.

Oncologist. 2019 Jul 19. pii: theoncologist.2019-0166. doi: 10.1634/theoncologist.2019-0166. [Epub ahead of print]

PMID:
31324663
7.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

de la Fouchardière C, Cohen R, Malka D, Guimbaud R, Bourien H, Lièvre A, Cacheux W, Artru P, François E, Gilabert M, Samalin-Scalzi E, Zaanan A, Hautefeuille V, Rousseau B, Senellart H, Coriat R, Flippot R, Desseigne F, Lardy-Cleaud A, Tougeron D.

Oncologist. 2019 May 31. pii: theoncologist.2018-0914. doi: 10.1634/theoncologist.2018-0914. [Epub ahead of print]

PMID:
31152084
8.

Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.

Bretagne JF, Piette C, Cosson M, Durand G, Lièvre A.

Dig Liver Dis. 2019 Oct;51(10):1461-1469. doi: 10.1016/j.dld.2019.05.004. Epub 2019 May 29.

PMID:
31151896
9.

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort.

Eur J Cancer. 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1.

PMID:
30826661
10.

Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.

Cacheux W, Lièvre A, Richon S, Vacher S, El Alam E, Briaux A, El Botty R, Mariani P, Buecher B, Schnitzler A, Barbazan J, Roman-Roman S, Bièche I, Dangles-Marie V.

Int J Cancer. 2019 Oct 1;145(7):1852-1859. doi: 10.1002/ijc.32178. Epub 2019 Feb 18.

PMID:
30714617
11.

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T, Le Sourd S, Pracht M, Manceau V, Lièvre A, Boudjema K, Garin E, Edeline J.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):669-676. doi: 10.1007/s00259-018-4199-5. Epub 2018 Oct 29.

12.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
13.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Sep;50(9):974-975. doi: 10.1016/j.dld.2018.06.014. Epub 2018 Jun 28. No abstract available.

14.

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2018 Aug;119(3):387. doi: 10.1038/s41416-018-0130-x.

15.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

16.

Immediate Effects of Thoracic Spine Thrust Manipulation on Neurodynamic Mobility.

Hartstein AJ, Lievre AJ, Grimes JK, Hale SA.

J Manipulative Physiol Ther. 2018 May;41(4):332-341. doi: 10.1016/j.jmpt.2017.10.006. Epub 2018 Apr 16.

PMID:
29669688
17.

Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.

Gauthé M, Richard-Molard M, Rigault E, Buecher B, Mariani P, Bellet D, Cacheux W, Lièvre A.

BMC Cancer. 2018 Apr 13;18(1):417. doi: 10.1186/s12885-018-4335-4.

18.

A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy.

Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, Boudjema K, Lievre A, Mesbah H, Haumont LA, Lenoir L, Brun V, Uguen T, Edeline J, Garin E.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1731-1741. doi: 10.1007/s00259-018-3990-7. Epub 2018 Mar 20.

PMID:
29560519
19.

[Metastatic colorectal cancer: To stop or not to stop?]

Artru P, Bennouna J, Lievre A, Ducreux M, Lledo G.

Bull Cancer. 2018 Apr;105(4):408-414. doi: 10.1016/j.bulcan.2017.12.010. Epub 2018 Feb 22. Review. French.

PMID:
29477654
20.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

21.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 May;50(5):507-512. doi: 10.1016/j.dld.2017.12.029. Epub 2018 Jan 8.

22.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C.

Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6.

PMID:
29258812
23.

Low participation in organized colorectal cancer screening in France: underlying ethical issues.

Moutel G, Duchange N, Lièvre A, Orgerie MB, Jullian O, Sancho-Garnier H, Darquy S.

Eur J Cancer Prev. 2019 Jan;28(1):27-32. doi: 10.1097/CEJ.0000000000000417.

24.

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2017 Dec 5;117(12):1819-1827. doi: 10.1038/bjc.2017.353. Epub 2017 Oct 12. Erratum in: Br J Cancer. 2018 Aug;119(3):387.

25.

Incidental colorectal focal 18 F-FDG uptake: a novel indication for colonoscopy.

Rigault E, Lenoir L, Bouguen G, Pagenault M, Lièvre A, Garin E, Siproudhis L, Bretagne JF.

Endosc Int Open. 2017 Sep;5(9):E924-E930. doi: 10.1055/s-0043-116384. Epub 2017 Sep 13.

26.

Fecal immunological blood test is more appealing than the guaiac-based test for colorectal cancer screening.

Le Pimpec F, Moutel G, Piette C, Lièvre A, Bretagne JF.

Dig Liver Dis. 2017 Nov;49(11):1267-1272. doi: 10.1016/j.dld.2017.08.018. Epub 2017 Aug 10.

PMID:
28867474
27.

Addressing low participant in colorectal cancer screening: Respect for individual freedom versus the community good.

Moutel G, Duchange N, Lièvre A, Darquy S.

Dig Liver Dis. 2017 Sep;49(9):1064-1065. doi: 10.1016/j.dld.2017.05.023. Epub 2017 Jun 21. No abstract available.

PMID:
28647391
28.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.

Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.

PMID:
28292641
29.

Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.

Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, Pracht M, Le Sourd S, Edeline J, Lièvre A.

Dig Liver Dis. 2017 Jun;49(6):692-696. doi: 10.1016/j.dld.2017.02.007. Epub 2017 Feb 14.

30.

Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis.

Bergeat D, Rayar M, Mouchel Y, Merdrignac A, Meunier B, Lièvre A, Boudjema K, Sulpice L.

Langenbecks Arch Surg. 2017 Feb;402(1):57-67. doi: 10.1007/s00423-017-1551-3. Epub 2017 Jan 13.

PMID:
28084516
31.

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.

Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A.

Cancer Chemother Pharmacol. 2017 Jan;79(1):9-16. doi: 10.1007/s00280-016-3193-5. Epub 2016 Nov 19.

PMID:
27866244
32.

Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.

Gauthé M, Richard-Molard M, Fayard J, Alberini JL, Cacheux W, Lièvre A.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):63-70. Epub 2016 Aug 9.

PMID:
27503193
33.

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.

Cacheux W, Rouleau E, Briaux A, Tsantoulis P, Mariani P, Richard-Molard M, Buecher B, Dangles-Marie V, Richon S, Lazartigues J, Jeannot E, Farkhondeh F, Sastre-Garau X, de La Rochefordière A, Labib A, Falcou MC, Stevens D, Roth A, Roman-Roman S, Mitry E, Bièche I, Lièvre A.

Br J Cancer. 2016 Jun 14;114(12):1387-94. doi: 10.1038/bjc.2016.144. Epub 2016 May 24.

34.

High-grade anal intraepithelial neoplasia: Progression to invasive cancer is not a certainty.

Gautier M, Brochard C, Lion A, Henno S, Mallet AL, Bodere A, Bouguen G, Lièvre A, Siproudhis L.

Dig Liver Dis. 2016 Jul;48(7):806-11. doi: 10.1016/j.dld.2016.03.011. Epub 2016 Mar 28.

35.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup.

Clin Colorectal Cancer. 2016 Sep;15(3):250-6. doi: 10.1016/j.clcc.2015.11.004. Epub 2015 Dec 2.

36.

Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.

Gauthé M, Lièvre A, Alberini JL.

Clin Nucl Med. 2015 Nov;40(11):e516-7. doi: 10.1097/RLU.0000000000000911.

PMID:
26204216
37.

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.

Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Lièvre A.

Cancer. 2015 Sep 15;121(18):3290-7. doi: 10.1002/cncr.29471. Epub 2015 Jun 5.

38.

Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.

Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD).

Dig Liver Dis. 2015 Jun;47(6):443-54. doi: 10.1016/j.dld.2015.02.005. Epub 2015 Feb 19. Review.

39.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V.

Cancer Res. 2015 Apr 15;75(8):1560-6. doi: 10.1158/0008-5472.CAN-14-1590. Epub 2015 Feb 24.

40.

Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centre.

Lièvre A, Laurent V, Cudennec T, Peschaud F, Malafosse R, Benoist S, Penna C, Lepère C, Vaillant JN, Julié C, Teillet L, Nordlinger B, Rougier P, Mitry E.

Dig Liver Dis. 2014 Sep;46(9):838-45. doi: 10.1016/j.dld.2014.05.005. Epub 2014 Jun 5.

PMID:
24908573
41.

Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.

Touchefeu Y, Archambeaud I, Landi B, Lièvre A, Lepère C, Rougier P, Mitry E.

Dig Liver Dis. 2014 Mar;46(3):283-6. doi: 10.1016/j.dld.2013.10.012. Epub 2013 Nov 20.

PMID:
24268567
42.

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.

Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin JL, Sabourin JC, Viguier J, Bastie A, Seronde A, Ducreux M.

Eur J Cancer. 2013 Jun;49(9):2126-33. doi: 10.1016/j.ejca.2013.02.016. Epub 2013 Mar 6.

PMID:
23473612
43.

Primary jejunal adenocarcinoma incidentally diagnosed on positron emission tomography/computed tomography in a patient with metastatic colorectal cancer: suspicion of Lynch syndrome and effect on therapeutic management.

Cacheux W, Lièvre A, Mariani P, Servois V, Farkhondeh F, Rouleau E, Buecher B, Petras S.

J Clin Oncol. 2013 Mar 20;31(9):e128-31. doi: 10.1200/JCO.2012.44.5833. Epub 2013 Jan 22. No abstract available.

PMID:
23341528
44.

Role of microsatellite instability in the management of colorectal cancers.

Buecher B, Cacheux W, Rouleau E, Dieumegard B, Mitry E, Lièvre A.

Dig Liver Dis. 2013 Jun;45(6):441-9. doi: 10.1016/j.dld.2012.10.006. Epub 2012 Nov 26. Review.

PMID:
23195666
45.

Chemotherapy in the treatment of anal canal carcinoma.

Cacheux W, Lievre A, De La Rochefordiere A, Dieumegard B, Cvitkovic F, Labib A, Mitry E, Buecher B.

Dig Liver Dis. 2012 Oct;44(10):803-11. doi: 10.1016/j.dld.2012.04.013. Epub 2012 May 30. Review.

PMID:
22658644
46.

Three different KRAS statuses in three synchronous colorectal cancers.

Jolissaint L, Cacheux W, Mariani P, Le Tourneau C, Lièvre A, Lappartient E, Margogne A, Farkhondeh F, de Cremoux P.

Med Oncol. 2012 Dec;29(4):2864-5. doi: 10.1007/s12032-012-0214-z. Epub 2012 Apr 1.

PMID:
22467075
47.

[Clinical significance of BRAF mutations in colorectal cancer].

Lièvre A, Rouleau E, Buecher B, Mitry E.

Bull Cancer. 2010 Dec;97(12):1441-52. doi: 10.1684/bdc.2010.1225. Review. French.

48.

[Biology applied to cancer treatments: the example of colorectal cancer].

Lièvre A, Laurent-Puig P.

Rev Prat. 2010 Oct 20;60(8):1100-2. French. No abstract available.

PMID:
21197742
49.

Oncogenic mutations as predictive factors in colorectal cancer.

Lièvre A, Blons H, Laurent-Puig P.

Oncogene. 2010 May 27;29(21):3033-43. doi: 10.1038/onc.2010.89. Epub 2010 Apr 12. Review.

PMID:
20383189
50.

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

Perkins G, Lièvre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, Laurent-Puig P.

Int J Cancer. 2010 Sep 1;127(6):1321-31. doi: 10.1002/ijc.25152.

Supplemental Content

Loading ...
Support Center